Commenting on the financial results, Axel Sven Malkomes, CFO, said: “Our decisive actions in 2024 to enhance fiscal discipline have significantly strengthened our financial foundation, securing a robust cash position that supports our runway into 2028. This financial strength provides CureVac (CVAC) with the flexibility and resources needed to accelerate innovation in our mRNA pipeline.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVAC:
- CureVac Receives FDA Clearance for Phase 1 Trial of mRNA Immunotherapy
- CureVac receives IND clearance to initiate Phase 1 trial for CVHNLC
- Biotech Alert: Searches spiking for these stocks today
- Lululemon reports Q4 beat, CoreWeave IPO priced at $40: Morning Buzz
- Morning Movers: U.S. Steel climbs following report of renewed Nippon talks